Case Report: Patient with Multiple Paragangliomas Treated with Long Acting Somatostatin Analogue

Endocrine Journal

Volumn 50, Issue 5, 2003, Pages 507-513

  Tonyukuk, Vedia ^a   Emral, Rifat ^a   Temizkan, Şule ^a   Sertçelik, Ayşe ^a   Erden, Ilhan ^a   Çorapçioǧlu, Demet ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Long acting somatostatin analogue; Multiple paragangliomas

Indexed keywords

LONG ACTING DRUG; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ADULT; ANAMNESIS; ARTICLE; ARTIFICIAL EMBOLISM; CANCER GROWTH; CASE REPORT; CLINICAL FEATURE; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; PARAGANGLIOMA; PERFORMANCE; QUALITY OF LIFE; SURGICAL TECHNIQUE; TUMOR SCINTISCANNING; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA; OCTREOTIDE; PARAGANGLIOMA; RADIONUCLIDE IMAGING;

EID: 0344010178     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.50.507     Document Type: Article

References (24)

1. Williams ED, Siebenmann RE, Sobin LH (1980) Histological typing of endocrine tumors. In: WHO International Histological Classification of Tumors. World Health Organization, Geneva 33-39.
2. Van Gils APG, van Erkel AR, Falke THM, Pauwels EKJ (1994) Magnetic resonance imaging or metaiodobenzylguanidine scintigraphy for the demonstration of paragangliomas? Correlation and disparities. Eur J Nucl Med 21: 239-253.
3. Maier W, Marangos N, Laszig R (1999) Paraganglioma as a systemic syndrome: pitfalls and strategies. J Laryngol Otology 113: 978-982.
4. Sobol SM, Bailey JC (1990) Familial multiple cervical paragangliomas: report of a hundred and review of the literature. Otolaryngol Head Neck Surg 102: 382-390.
5. Grufferman S, Gillman MW, Pasternak LR, Peterson CL, Young WG Jr (1990) Familial carotid body tumors: case report and epidemiologic review. Cancer 46: 2116-2122.
6. Erickson D, Kudva YC, Ebersold MJ, Thompson BG, Grant CS, Heerden JA, Young WF Jr (2001) Benign paragangliomas: Clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab 86 (11): 5210-5216.
7. Wax M, Briant D (1992) Carotid body tumors: a review. J Otolaryngol 21: 4.
8. Somasundar P, Krouse R, Hostetter R, Vaughan R, Covey T (2000) Paragangliomas - A decade of clinical experience. J Surg Oncology 74: 286-290.
9. Young WF Jr (1997) Pheochromocytoma: How to catch a moonbeam in your hand. Eur J Endocrinol 136: 28-29.
10. Van Gelder T, Verhoeven GT, de Jong P, Oei HY, Krenning EP, Vuzevski VD, van der Meiracker AH (1995) Dopamine-producing paraganglioma not visualized by iodine-123-MIBG scintigraphy. J Nucl Med 36 (4): 620-622.
11. Troncone L, Rufini V (1998) Radiolabelled metaiodobenzylguanidine in the diagnosis of neural crest tumors. In: Murray PC, Ell PJ (eds) Nuclear Medicine in Clinical Diagnosis and Therapy. Churchill Livingstone, Edinburgh, Vol 2: 843-857.
12. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi JC (1995) Somatostatin receptor scintigraphy. In: Freeman LM (ed) Nuclear Medicine Annual. Raven Press, New York, 1-50.
13. Troncone L, Rufini V (1999) Nuclear medicine therapy of pheochromocytoma and paraganglioma. Q J Nucl Med 43: 344-355.
14. Kwekkeboom DJ, van Urk H, Pauw BKH, Lamberts SWJ, Kooij PPM, Hoogma RPLM, Krenning EP (1993) Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med 34: 873-878.
15. Tenenbaum F, Lumbroso J, Schlumberger M, Mure A, Plouin PF, Caillou B, Parmentier C (1995) Comparison of radiolabelled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med 36: 1-6.
16. Tenenbaum F, Schlumberger M, Lumbroso J, Parmentier C (1996) Beneficial effects of octreotide in a patient with a metastatic paraganglioma. Eur J Cancer 32A: 737-738.
17. Arraras JI, Arias F, Tejedor M, Pruja E, Marcos M, Martinez E, Valerdi J (2002) The EORTC QLQ-C30 (version 3.0) Quality of Life questionnaire: validation study for Spain with head and neck cancer patients. Psychooncology 11: 249-256.
18. Muros MA, Llamas-Elvira JM, Rodriguez A, Ramirez A, Gomez M, Arraez MA, Valencia E, Vilchez R (1998) 111-Indium-pentetreotide scintigraphy is superior to 123-Iodine-MIBG scintigraphy in the diagnosis and location of chemodectoma. Nucl Med Commun 19: 735-742.
19. Eriksson B, Öberg K (1999) Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: Future outlook. Ann Oncology 10 (Suppl 2): 31-38.
20. Lamberts SWJ, van der Lely AJ, De Herder WW, Hofland LJ (1996) Octreotide. N Engl J Med 334: 246-254.
21. Weckbecker G, Stolz B, Susini Ch, Bruns Ch (1999) Antiproliferative somatostatin analogues with potential in oncology. In: Lamberts SWJ (ed) Octreotide: The Next Decade. Bioscientifica, Bristol, UK, 339-352.
22. Barrie R, Woltering EA, Hajarizadeh H, Mueller C, Ure T, Fletcher WS (1993) Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res 55: 446-450.
23. Wynick D, Anderson JV, Williams SJ, Bloom SR (1989) Resistance of metastatic pancreatic endocrine tumors after long-term treatment with the somatostatin analogue octreotide (SMS 201-995). Clin Endocrinol 30: 385-388.
24. Harris AG, Kokoris SP (1993) Therapeutic applications of somatostatin and its analogue octreotide. Eur J Med 2: 97-105.